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Abstract 
Gastrointestinal stromal tumors (GISTs) are
rare,  but  represent  the  most  common  mes-
enchymal  neoplasms  of  the  gastrointestinal
tract.  Tumor  resection  is  the  treatment  of
choice for localized disease. Tyrosine kinase
inhibitors (imatinib, sunitinib) are the stan-
dard  therapy  for  metastatic  or  unresectable
GISTs. GISTs usually metastasize to the liver
and peritoneum. Bone metastases are uncom-
mon.  We describe three cases of bone metas-
tases  in  patients  with  advanced  GISTs:  two
women (82 and 54 years of age), and one man
(62 years of age). Bones metastases involved
the spine, pelvis and ribs in one patient,  mul-
tiple vertebral bodies and pelvis in one, and the
spine and iliac wings in the third case. The
lesions presented a lytic pattern in all cases.
Two  patients  presented  with  multiple  bone
metastases at the time of initial diagnosis and
one patient after seven years during the follow-
up period. This report describes the diagnosis
and treatment of the lesions and may help cli-
nicians to manage bones metastases in GIST
patients.
Introduction
Gastrointestinal stromal tumors (GISTs) are
rare,  but  represent  the  most  common  mes-
enchymal  neoplasms  of  the  gastrointestinal
tract. The most frequent site of occurrence is
the stomach (60% of cases), followed by the
small bowel (35%) and other sites (colon, rec-
tum, oesophagus <5%).1 GISTs may also devel-
op as primary tumors of the omentum, mesen-
tery or retroperitoneum. They are classified as
spindle cell, epithelioid or pleomorphic mes-
enchymal tumors of the GI tract. Tumor resec-
tion is the treatment of choice for localized dis-
ease. The risk of recurrence is identified eval-
uating the mitotic index, dimension and site of
the  tumor.2,3 Selective  tyrosine  kinase
inhibitors (imatinib, sunitinib) are the stan-
dard  therapy  for  metastatic  or  unresectable
GISTs.4,5 Evaluation of tumor response to this
molecular  target  therapy,  is  very  important
because a decrease in tumor size (RECIST cri-
teria) is not adequate since target therapies do
not always affect tumor dimensions but usual-
ly  lead  to  metabolic  and  densitometric
changes.6 Other CT scan parameters and PET
imaging  have  been  established  to  assess
tumor response more accurately (CHOI crite-
ria).7
GISTs usually metastasize to the liver and
peritoneum.  Rare  sites  of  metastasis  are
lymph-nodes,  lung  and  subcutaneous  tissue,
and intracranial localizations have only been
described in a case report.8-10 Bone metastases
are also uncommon.11-14
We describe three cases of bone metastases
in patients with advanced GISTs. Two of them
showed bone metastases at disease presenta-
tion, whereas the third patient was diagnosed
after several years of follow-up.  
Case #1 
A  62-year-old  man  presented  to  the
Emergency Room in April 2004 with acute lum-
bar  back  pain.  Multiple  hepatic  and  skeletal
metastases were detected involving the spine,
pelvis  and  ribs  with  a  lytic  pattern  (Figure
1A,B,C).  A  CT  scan  disclosed  the  primary
tumor as an abdominal mass of 8 cm, contigu-
ous to ileal loops. Liver biopsy revealed a GIST.
The  immunoistochemical  analysis  revealed
the tumor was positive CD 117 and CD 34, neg-
ative  S100,  mitotic  index  was  not  available.
One month later, the patient started imatinib
400  mg/die,  and  zoledronic  acid  concurrent
with radiotherapy on the spine (from T12 to L2
with a total dose of 3000 cGy). The patient had
a clinical benefit and disease stability for two
years. In 2006, when the patient was referred
to us, a disease progression was documented.
Zoledronic acid was stopped due to mandibular
osteonecrosis. The patient was then enrolled
in a clinical protocol with sunitinib and the
disease was stable until January 2007 when
the patient’s clinical conditions worsened. He
died in February 2007 from pulmonary edema
and acute renal failure.
Case #2
An  82-year-old  woman  underwent  several
examinations in October 2006 for acute ane-
mia. A CT scan disclosed a gastric lesion with
hepatic and bone metastases. Many vertebral
bodies  and  the  pelvis  were  involved  and  the
lesions  had  a  lytic  pattern  (Figure  2).  She
underwent  a  partial  gastric  resection.  The
tumor size was 8.5 cm, the mitotic index was
16/50  High  Power  Field  (HPF)  and  the
immunoistochemical  analysis  revealed  the
tumor was positive CD 117 and CD 34, negative
S100. The tumor presented KIT exon 11 muta-
tion  (KIT  exon  11  c.1696_1718del
(p.N566_P573delinsA).  She  started  imatinib
400 mg/die and zoledronic acid with disease sta-
bility until April 2009 when an increase in size
of a lesion in the right iliac fossa was document-
ed in spite of stable hepatic and bone metas-
tases. The patient started imatinib 800 mg/die,
but she had to suspend the drug in July 2009
due to intolerance. Since June 2010 she has
been taking sunitinib 37.5 mg/ die and is well. 
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Case #3 
A 54-year-old woman came to our attention
for a duodenal mass. In 2001 she had under-
gone  a  segmentary  resection  of  the  small
intestine. The tumor size was 4 cm, mitotic
index  was  >5/50  HPF  and  the  immunoisto-
chemical analysis revealed the tumor was pos-
itive CD 117 and CD 34. The tumor presented
KIT exon 11 mutation (KIT exon 11 T>A 69429
(p.V559d). In 2002, because of tumor recur-
rence with multiple hepatic lesions, she start-
ed a treatment with imatinib 400 mg/die with
disease stability until February 2005. At that
time, a CT scan documented disease progres-
sion in the liver, so a treatment with imatinib
800 mg/die was started. In November 2005, a
new progression led to a second-line protocol
with sunitinib 37.5 mg/die. This new therapy
stabilized  the  multiple  hepatic  lesions  until
March 2007 when an increase in size and vas-
cularisation of the lesions was diagnosed. In
July  she  started  a  new  treatment  with  nilo-
tinib. In April 2008 the patient complained of
severe pain in the right intercostal site, not
controlled by analgesic therapy. A CT scan dis-
closed stable abdominal disease but multiple
osteolytic  bone  metastases  had  appeared  in
her ribs (with pathologic fractures), spine and
iliac wings. In particular, the osteolytic metas-
tasis of the left iliac wing was induced by a
solid pathologic tissue eroding the bone cortex
and invading adjacent tissues (Figure 3A). The
patient  again  received  sunitinib  but  had  to
suspend the drug because of intolerance. A CT
scan in January 2009 showed an enlargement
of the iliac bone metastasis (Figure 3B) with
the  appearance  of  new  lesions.  The  patient
died in August 2009 from progressive disease.
Discussion
In the past seven years, we have followed-up
71 patients with GISTs. Among them, we dis-
covered  three  cases  of  bone  metastases.
Clinically, bone metastases were symptomatic
in two patients and presenting with a patholog-
ical  fracture  in  a  single  case.  In  only  one
patient bone lesions were asymptomatic and
diagnosed as occasional finding. Two patients
had bone metastases at disease presentation
and in one of them bone pain led to diagnosis
of the primary tumor. In the third patient, bone
metastases were found many years after diag-
nosis of the primary tumor. Medical therapy
with  zoledronic  acid  in  association  with  TK
inhibitors yielded long-term disease stabiliza-
tion in two cases, whereas the disease pro-
gressed rapidly in the third patient. Only one
patient was also treated with radiotherapy for
palliative purpose.
Bone metastases in GISTs are rare, but they
are encountered more frequently than in the
past. This is probably due to advances in imag-
ing techniques and to an improvement in over-
all patient survival following the introduction
of tyrosine kinase inhibitors.
Diagnosis of bone metastases in GISTs is
often  based  on  clinical  findings  alone  (i.e.
bone fractures or bone pain) or is occasionally
made  during  imaging  evaluation.  We  think
more attention should be paid to the diagnosis
of bone metastases in clinical practice despite
the dearth of available data on the sensitivity
and specificity of bone scintigraphy and PET. 
CT  scan  in  our  three  patients  disclosed
unknown bone metastases. The lesions were
mostly lytic, with a complete rearrangement of
bone  structure,  cortex  erosion  and,  in  one
case, a solid mass invading adjacent soft tis-
sues. The most frequent sites of bone metas-
tases were spine and pelvis.
Few data can be found in literature on the
treatment of bone metastases in GISTs. The
effect of imatinib on bone lesions is unknown
as  is  the  activity  of  zoledronic  acid,  even
though  it  may  be  recommended.  Zoledronic
acid is a bisphosphonate administered intra-
venously. It is the current standard therapy for
osteoporosis and is used to combat hypercal-
cemia and bone metastases from solid tumors
in the colon, breast, lung, prostate and renal
cell  carcinoma.15,16 Zoledronic  acid  has  also
proved effective in the prevention and treat-
ment  of  bone  localizations  in  patients  with
multiple myeloma. Zoledronic acid penetrates
osteoclast cells selectively and promotes their
apoptosis, thereby reducing bone resorption.17
The drug also reduces the frequency of bone
events and bone pain and improves quality of
life.16-18 In vitro studies have demonstrated the
antitumor  properties  of  zoledronic  acid,19-22
and  the  role  of  this  targeted  therapy  in  the
Case Report
Figure 1. (A) Multiple lytic lesions of the
ribs and vertebral body. (B) Multiple lytic
lesions of the spine with vertebral collapse.
(C) Multiple lytic lesions of the pelvis.
Figure 2. Sacral lytic lesion.
Figure 3. (A) Lytic lesion of the left iliac
wing. (B) Enlargement of the iliac lesion.[Rare Tumors 2011; 3:e17] [page 53]
management  of  patients  with  GISTs  merits
investigation.  Radiotherapy  and  orthopedic
surgery can also be adopted in the treatment of
bone metastases in GISTs, but they have a pal-
liative role, reducing bone pain or preventing
pathologic fractures and other skeletal-related
events.  There  are  no  standard  criteria  for
imaging  or  metabolic  assessment  of  tumor
response, and few data are available on densi-
ty changes in bone metastases after therapy. 
Likewise, the clinical and molecular risk fac-
tors  for  bone  metastases  have  yet  to  be
defined. The primary tumours in our patients
were localized in three different sites (small
intestine, stomach and duodenum) and meas-
ured 3 cm in case 1, 8.5 cm in case #2 and 4 cm
in case 3. The mitotic index was not available
for case 1, was 16/50 HPF for case #2, and 5-10
/50 for case #3. Molecular analysis was per-
formed in two patients (cases #2 and #3) and
both presented a KIT exon 11 mutation (KIT
exon  11  c.1696_1718del  (p.N566_P573
delinsA)  case  1;  KIT  exon  11  T>A  69429
(p.V559d) case #2). Hence, there was no corre-
lation in our small cohort between GISTs clini-
cal  and  pathological  presentation,  GISTs
molecular  status  and  bone  metastases.  A
molecular  analysis  of  bone  metastases  may
serve  to  disclose  any  secondary  KIT  and
PDGFRA  mutations  associated  with  bone
metastatic spread. 
In conclusion, bone metastases from GISTs
are rare, but they may become more prevalent
due to increased patient life expectancy as well
as  the  improvement  in  imaging  techniques
and they should always be sought. Data on risk
factors,  molecular  background,  treatment
response and prognostic significance are not
defined yet and should be collected in a larger
series. 
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